Skip to search formSkip to main contentSkip to account menu

Xarelto

National Institutes of Health

Related topics

Related topics

2 relations
Xarelto Pill

Broader (1)

rivaroxaban

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
THYROID DISORDERS CASE REPORTS II An Atypical Presentation of Severe Hypothyroidism, a Case of Large Posterior Pericardial Effusion Without Hemodynamic Compromise
A340 JESOCI, Volume 4, Abstract Supplement, 2020 Healthcare professionals who serve in roles involving diabetes care and glycemic… 
2020
2020
SUN-124 Are Venous Thromboembolic Events Increased in MEN1 Patients?
Abstract Background: Multiple endocrine neoplasia type 1 (MEN1) is a rare inherited disorder in which patients develop multiple… 
2019
2019
Une pneumopathie anormalement confusogène chez une grand-mère
2019
2019
Bayer and Janssen pay $775m to settle Xarelto misinformation claims
The German drug maker Bayer and the Johnson & Johnson subsidiary Janssen Pharmaceuticals will jointly pay $775m (£587m; €687m) to… 
Review
2018
Review
2018
Cerebral Venous Thrombosis and Sickle Cell (SC) Disease: Case Report and Literature Review
The authors report a case of cerebral venous thrombosis in a thirty-seven-year-old sickle cell (SC) patient, who presented with a… 
Review
2018
Review
2018
Xarelto (Rivaroxaban) Prophylaxis Reduces the Risk of Thromboembolic Events Following Knee Osteotomy Without Increased Bleeding Complications
Review
2012
Review
2012
RIVAROXABAN (XARELTO) VS. ENOXAPARIN (CLEXANE): A COMPARISON OF ACUTE POSTOPERATIVE MORBIDITY FOLLOWING TOTAL KNEE REPLACEMENT
Rivaroxaban is an oral anticoagulant which has the potential to replace subcutaneous Clexane in post operative prophylaxis of… 
Review
2010
Review
2010
Entering the era of non-basic p1 site groups: discovery of Xarelto (Rivaroxaban).
Several clinical candidates have now emerged as a result of an intense search for orally available, antithrombotic factor Xa… 
2009
2009
[Rivaroxaban (Xarelto): new anticoagulant inhibitor of factor Xa].
(Xarelto, Bayer Schering Pharma) is a new anticoagulant with a good oral bioavailability, acting as a potent, selective direct… 
2005
2005
One Bright Spot
The best ebooks about One Bright Spot that you can get for free here by download this One Bright Spot and save to your desktop… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)